The HFSA Annual Scientific Meeting 2023 is where heart failure teams gather! In 2023, we’ll bring you the best of heart failure science, research and practical management and connection opportunities. ASM 2023 will be held October 6-9, 2023 at the Huntington Convention Center in Cleveland, Ohio.
The Heart Failure Society of America (HFSA) will host the 4th annual program of education and support for heart failure patients and caregivers on October 6, 2023 in conjunction with the HFSA Annual Scientific Meeting 2023 in Cleveland, OH! The program will provide patients and caregivers the opportunity to participate in educational discussions with leading heart failure experts.
Hypertrophic cardiomyopathy (HCM) is estimated to affect some 700,000 Americans. Treatment usually includes the use of non-vasodilating beta-blockers followed by non-dihydropyridine calcium channel blockers if these therapies are not effective. Since the release of the most recent guidelines, mavacamten has been approved, and clinical trial data on emerging therapies including aficamten, ranolazine, and evolving gene therapies have been published. In our commitment to providing education that enhances clinical skills and improves patient outcomes, HFSA has identified a need for education in the selection and utilization of current and emerging therapies for HCM.
The HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM) is part of the educational seminar series, featuring a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.